There have been a number of incidents in recent years that have raised concerns about the stability of medical supplies. In 2020, the Japanese Ministry of Health, Labour and Welfare designated 506 drugs as requiring stable supplies during crises, including 10 psychotropics. However, these psychotropics were not selected based on the views of all stakeholders in mental healthcare. In the present study, we conducted a web-based questionnaire survey of psychiatrists (n=1,210), pharmacists (n=217), and patients/their families (n=153) regarding psychotropics that require stable supplies during crises, followed by a consensus survey based on a modified Delphi panel at a symposium held at the 118th Annual Meeting of the Japanese Society of Psychiatry and Neurology. The questionnaire survey revealed that more than 90% of psychiatrists and pharmacists and more than 80% of patients/their families accepted the selection of 10 psychotropics as medicines that require stable supplies during crises. In addition, a consensus survey selected four antipsychotics (risperidone, aripiprazole, olanzapine, and quetiapine), two antidepressants (mirtazapine and escitalopram), two mood stabilizers (sodium valproate and lithium carbonate), one anxiolytic (lorazepam), and one hypnotic (lemborexant) as psychotropics that require stable supplies during crises.
Authors' abstract
A Web-based Survey on Psychotropics that Require Stable Supplies during Crises in the Japanese Mental Healthcare Setting
1 College of Education, Psychology and Human Studies, Aoyama Gakuin University
2 Health Administration Center, Aoyama Gakuin University
3 Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry
4 Department of Psychiatry, Kitasato University School of Medicine
5 Department of Neuropsychiatry, Kyorin University School of Medicine
6 Department of Neuropsychiatry, Akita University Graduate School of Medicine
7 Cognitive and Molecular Research Institute of Brain Diseases, Kurume University
8 Department of Neuropsychiatry, Kurume University School of Medicine
9 Health Management Office, SMBC Nikko Securities inc.
10 Life Grow Brilliant Mental Clinic, Medical Corporation Foster
11 Department of Educational Promotion, Clinical Research & Education Promotion Division, National Center of Neurology and Psychiatry
12 Hyogo Prefecture-Hyogo Mental Health Center
13 Department of Neuropsychiatry, Kansai Medical University
14 Fujisawa Hospital
15 Hills Joint Research Laboratory for Future Preventive Medicine and Wellness, Keio University School of Medicine
16 Department of Child and Adolescent Psychiatry, Hokkaido University Hospital
17 Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University
18 Department of Psychiatry, Dokkyo Medical University School of Medicine
19 Department of Psychiatry, Faculty of Medicine, Saitama Medical University
20 Miki Mental Clinic
21 Mino Clinic
22 Department of Neuropsychiatry, Keio University School of Medicine
2 Health Administration Center, Aoyama Gakuin University
3 Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry
4 Department of Psychiatry, Kitasato University School of Medicine
5 Department of Neuropsychiatry, Kyorin University School of Medicine
6 Department of Neuropsychiatry, Akita University Graduate School of Medicine
7 Cognitive and Molecular Research Institute of Brain Diseases, Kurume University
8 Department of Neuropsychiatry, Kurume University School of Medicine
9 Health Management Office, SMBC Nikko Securities inc.
10 Life Grow Brilliant Mental Clinic, Medical Corporation Foster
11 Department of Educational Promotion, Clinical Research & Education Promotion Division, National Center of Neurology and Psychiatry
12 Hyogo Prefecture-Hyogo Mental Health Center
13 Department of Neuropsychiatry, Kansai Medical University
14 Fujisawa Hospital
15 Hills Joint Research Laboratory for Future Preventive Medicine and Wellness, Keio University School of Medicine
16 Department of Child and Adolescent Psychiatry, Hokkaido University Hospital
17 Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University
18 Department of Psychiatry, Dokkyo Medical University School of Medicine
19 Department of Psychiatry, Faculty of Medicine, Saitama Medical University
20 Miki Mental Clinic
21 Mino Clinic
22 Department of Neuropsychiatry, Keio University School of Medicine
Psychiatria et Neurologia Japonica
125: 932-943, 2023
https://doi.org/10.57369/pnj.23-133
Accepted in revised form: 29 July 2023.
https://doi.org/10.57369/pnj.23-133
Accepted in revised form: 29 July 2023.
＜Keywords：psychotropics, stable supply, questionnaire survey, consensus survey＞
